Mackenzie Financial
NVCR icon

Mackenzie Financial’s NovoCure NVCR Stock Holding History

Mackenzie Financial’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$18.8M Buy
1,176,709
+1,128,237
+2,328% +$18.8M 0.02% 472
2026
Q2 		$734K Buy
+48,472
New +$733K ﹤0.01% 1245
2025
Q3 		– Sell
-66,152
Closed -$1.18M – 1798
2025
Q2 		$1.18M Buy
+66,152
New +$1.15M ﹤0.01% 973
2025
Q1 		– Sell
-6,820
Closed -$203K – 1759
2024
Q4 		$203K Buy
+6,820
New +$144K ﹤0.01% 1562
2022
Q1 		– Sell
-12,078
Closed -$907K – 1476
2021
Q4 		$907K Buy
12,078
+4,620
+62% +$464K ﹤0.01% 921
2021
Q3 		$866K Buy
7,458
+3,282
+79% +$496K ﹤0.01% 927
2021
Q2 		$926K Buy
+4,176
New +$812K ﹤0.01% 891
2018
Q2 		– Sell
-23,600
Closed -$514K – 1042
2018
Q1 		$514K Buy
+23,600
New +$508K ﹤0.01% 729

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Quantinno Capital Management
Quantinno Capital Management New York $106B AUM 29.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Mackenzie Financial's NVCR Position: Q3 2026 in Review

Mackenzie Financial increased its NovoCure (NVCR) stake by 2,328% in Q3 2026, buying an estimated $18.8M and bringing the position to 1,176,709 shares worth $18.8M. The position accounts for 0.02% of the portfolio, ranked #472.

Mackenzie Financial first reported a position in NVCR in Q1 2018 and has held it in 8 quarters since. 183 funds tracked by Wall St. Rank hold NVCR as of Q3 2026.

  • Mackenzie Financial held 1,176,709 shares of NovoCure worth $18.8M as of Q3 2026.
  • Mackenzie Financial bought 1,128,237 NovoCure shares in Q3 2026, an estimated $18.8M.
  • NovoCure made up 0.02% of Mackenzie Financial's portfolio in Q3 2026, its #472 holding.
  • Mackenzie Financial first reported a position in NovoCure in Q1 2018 and has held it in 8 quarters since.
  • 183 funds tracked by Wall St. Rank held NovoCure as of Q3 2026.

Based on Mackenzie Financial's 13F filing for Q3 2026, filed 2 Nov 2026.